Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | March 04, 2021 | March 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date March 04, 2021 · Filed March 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,427 |
Reported balance
After 2021-03-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-04 · Sale · Disposed 8,168 · Balance 24,427 F1: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2: These shares are held of record by a living trust, for which the Reporting Person serves as Trustee. F3: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $91.01 to $93.50. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.
F2: These shares are held of record by a living trust, for which the Reporting Person serves as Trustee.
F3: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $91.01 to $93.50.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2021 Filed Mar 8, 2021 18:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 8,168 | $92.37 | $754,478.16 |
DisclosureSEC source: 0001367644-21-000051 · wf-form4_161524624160313.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,427 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These shares are held of record by a living trust, for which the Reporting Person serves as Trustee. F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $91.01 to $93.50. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 17:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,665 | $128.31 | $598,563.82 |
DisclosureSEC source: 0001367644-20-000139 · wf-form4_159787126712250.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,595 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices between $128.25 and $128.47. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 16:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,322 | $87.50 | $465,690.97 |
DisclosureSEC source: 0001367644-20-000100 · wf-form4_159138920953180.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,260 F1 · security: Consists of stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $86.64 to $88.65. Read SEC document |
| May 21, 2020 Filed May 26, 2020 08:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000070 · wf-form4_159049649319393.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,582 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,572 | $56.93 | $374,132.13 |
DisclosureSEC source: 0001367644-20-000023 · wf-form4_158318811165658.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,761 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan, as amended. F2 · price: The price reported is the weighted average sale price. These shares were sold in multiple transactions in prices ranging from $56.50 to $57.49. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 09:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 8,375 | $53.46 | $447,727.50 |
DisclosureSEC source: 0001367644-19-000069 · wf-form4_157624687889376.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,333 F1 · security: Consists of restricted stock units granted under the Company's stock incentive plan, as amended and restated. F2 · price: The price reported is the weighted average sale price. These shares were sold in multiple transactions in prices ranging from $53.08 to $53.82. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012273 · doc1.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,708 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 3,158 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · derivative · entry 12 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,158 shares Expires 2019-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 4,736 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · derivative · entry 11 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,736 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 1,579 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · derivative · entry 10 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,579 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 8,244 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · derivative · entry 9 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,244 shares Expires 2021-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,158 | $69.62 | $219,859.01 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · nonDerivative · entry 8 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,972 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.05, inclusive. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,158 | $13.37 | $42,222.46 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · nonDerivative · entry 7 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,736 | $69.62 | $329,718.90 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · nonDerivative · entry 6 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,972 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.05, inclusive. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 4,736 | $13.00 | $61,568.00 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · nonDerivative · entry 5 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,579 | $69.62 | $109,929.51 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · nonDerivative · entry 4 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,972 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.05, inclusive. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 1,579 | $20.08 | $31,706.32 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · nonDerivative · entry 3 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 8,244 | $69.62 | $573,944.81 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · nonDerivative · entry 2 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,972 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.05, inclusive. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 8,244 | $18.64 | $153,668.16 |
DisclosureSEC source: 0001567619-18-007116 · doc1.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2018 Filed May 24, 2018 18:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025558 · doc1.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,972 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| May 25, 2017 Filed May 26, 2017 13:46 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022469 · doc1.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,077 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 2,061 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 27 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,244 Underlying: Common Stock · 2,061 shares Expires 2021-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 3,157 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 25 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,736 Underlying: Common Stock · 3,157 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 4,735 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 23 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 Underlying: Common Stock · 4,735 shares Expires 2019-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 3,157 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 21 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,579 Underlying: Common Stock · 3,157 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 3,157 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 19 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,157 shares Expires 2020-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 3,157 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 17 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,157 shares Expires 2019-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,061 | $29.78 | $61,374.31 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 15 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 2,061 | $18.64 | $38,417.04 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 14 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,157 | $29.78 | $94,011.99 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 13 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,157 | $13.00 | $41,041.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 12 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,735 | $29.78 | $141,003.09 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 11 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 4,735 | $13.37 | $63,306.95 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 10 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,157 | $29.78 | $94,011.99 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 9 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,157 | $20.08 | $63,392.56 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 8 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,157 | $29.78 | $94,011.99 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 7 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,157 | $14.71 | $46,439.47 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 6 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,157 | $29.78 | $94,011.99 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 5 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,157 | $10.64 | $33,590.48 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 4 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherStock Option (Right to buy) · Derivative | 905 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 26 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,305 Underlying: Common Stock · 905 shares Expires 2021-05-21 F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherStock Option (Right to buy) · Derivative | 693 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 24 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 Underlying: Common Stock · 693 shares Expires 2020-05-22 F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherStock Option (Right to buy) · Derivative | 693 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 22 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 Underlying: Common Stock · 693 shares Expires 2019-05-16 F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherStock Option (Right to buy) · Derivative | 416 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 20 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,736 Underlying: Common Stock · 416 shares Expires 2021-05-18 F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherStock Option (Right to buy) · Derivative | 277 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 18 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,157 Underlying: Common Stock · 277 shares Expires 2020-05-19 F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherStock Option (Right to buy) · Derivative | 277 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 16 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,157 Underlying: Common Stock · 277 shares Expires 2019-05-20 F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 3 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F3 · security: In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 2 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,241 F2 · security: In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018. Read SEC document |
| August 01, 2016 Filed Jan 19, 2017 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 152 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,637 F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.